0940 GMT - AI could help pharmaceutical companies shorten their drug-development processes, but the complexity of human biology remains the ultimate bottleneck, UBS analysts say in a research note. AI is currently being deployed to make drugmakers' operations more efficient in areas like regulatory documentation and financial processes, as opposed to core drug discovery, the analysts say, citing comments from executives at a recent conference hosted by UBS. "Management teams clearly stated that AI can help identify targets in early drug discovery, but that it is ultimately still limited in its ability to reliably design drugs that achieve a predicted clinical outcome," the analysts say. The Stoxx Europe 600 Health Care index is up 0.1%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 13, 2026 05:43 ET (09:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.